Newfeed

Advisory Committee Voted 10 to 6 in Favor, Concluding that Elamipretide is Effective for the Treatment of Barth Syndrome Elamipretide NDA Received Priority Review with a PDUFA Action Date of January 29, 2025 If Approved, Elamipretide Would Be the First Therapy for Barth Syndrome, a Life-Threatenin

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB’s leadership in neuromuscular researchPresentations showcase new data for UCB’s gMG treatments, including post hoc analyses highlighting the long-

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: